Combinations of single gene predictors with AI-driven polygenic precision therapies in cardiovascular diseases.

Combining single-gene predictors (*CYP2C19*, *SLCO1B1*, *VKORC1*) with polygenic approaches for cardiovascular therapeutic precision

This narrative review in Pharmacogenomics synthesizes clinical evidence for pharmacogenomics in cardiovascular diseases, combining actionable single-gene predictors (CYP2C19 for post-PCI antiplatelets, SLCO1B1 for statins, VKORC1/CYP2C9 for warfarin) with emerging polygenic approaches and AI-assisted clinical decision integration.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Cardiovascular PGx is one of the most clinically mature fields, but the interplay between single-gene predictors (immediately actionable) and polygenic approaches (promising but not yet standardized) remains complex. This review offers a useful overview for teams planning preemptive genotyping programs.

Clinical impact: 2/3 · Evidence strength: 2/3 · Novelty: 1/2 · Sample size: 0/1 · Publication status: 1/1 → Total: 6/10